Psychotic Disorders - Norway | Statista Market Forecast

Revenue in the Psychotic Disorders market is projected to reach US$50.79m in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2029) of 0.71%, resulting in a market volume of US$52.62m by 2029.
In global comparison, most revenue will be generated United States (US$2.26bn in 2024).
In relation to total population figures, per person revenues of US$759.70 are generated in 2024.

Psychotic disorders are severe mental health disorders that cause changes in a person's way of thinking and their perception. Patients often have trouble differentiating between what they perceive and reality. Different types of psychotic disorders include schizophrenia, bipolar disorder, substance-induced psychotic disorder, delusional disorder, and brief psychotic disorder. However, this market only represents the sales of antipsychotic drugs that are used to treat schizophrenia and bipolar disorder.

Market values represent the revenues generated by manufacturers and are based on retail prices for each drug category including all drugs, regardless of whether they are reimbursed or not.

Company examples: Otsuka Pharmaceutical, Lundbeck, AbbVie, Allergan plc, Recordati S.p.A., Gadeon Richter, Sumitomo Pharma, Johnson & Johnson / Janssen, Vanda Pharmaceuticals, Alkermes, Eli Lilly, AstraZeneca, and Intra-Cellular Therapies

Antipsychotic drugs: Aripiprazole (Abilify), Asenapine (Saphris), Cariprazine (Vraylar), Clozapine (Clozaril, Versacloz), lumateperone (Caplyta), Lurasidone (Latuda), Olanzapine (Zyprexa), Quetiapine (Seroquel), Risperidone (Risperdal), Risperidone (Aristada), Ziprasidone (Geodon), Brexpiprazole (Rexulti), Iloperidone (Fanapt), and Paliperidone (Invega)

Psychotherapy
Talk therapy
Herbal medicines
Digital health apps
Deep Brain Stimulation (DBS)

The Psychotic Disorders market in Norway is experiencing steady growth due to changing customer preferences, emerging trends in the market, and local special circumstances.

Customer preferences: Customers in Norway are increasingly seeking effective treatments for psychotic disorders, leading to a growing demand for medications and therapies. They are looking for innovative and evidence-based solutions that can effectively manage symptoms and improve quality of life. Additionally, there is a growing preference for personalized treatment plans that take into account individual needs and preferences.

Trends in the market: One of the key trends in the Psychotic Disorders market in Norway is the shift towards holistic and multidisciplinary approaches to treatment. Healthcare providers are recognizing the importance of addressing not only the symptoms of psychotic disorders, but also the underlying causes and associated comorbidities. This has led to the integration of various treatment modalities, including medication, psychotherapy, and social support services. Furthermore, there is a growing emphasis on early intervention and prevention strategies to minimize the long-term impact of psychotic disorders.Another trend in the market is the increasing use of digital health solutions for managing psychotic disorders. Mobile applications, online platforms, and wearable devices are being developed to support self-management, provide educational resources, and facilitate remote monitoring. These digital tools offer convenience, accessibility, and real-time support for individuals with psychotic disorders, as well as their caregivers.

Local special circumstances: Norway has a well-developed healthcare system that provides universal access to healthcare services, including mental health care. The government has implemented policies and initiatives to improve mental health services and reduce the stigma associated with psychotic disorders. This has led to increased awareness, diagnosis, and treatment rates in the country. Additionally, Norway has a high level of healthcare expenditure, which allows for the adoption of innovative treatments and technologies in the Psychotic Disorders market.

Underlying macroeconomic factors: The growth of the Psychotic Disorders market in Norway is also influenced by underlying macroeconomic factors. The country has a high GDP per capita, which indicates a strong purchasing power and willingness to invest in healthcare. Furthermore, Norway has a stable economy and low unemployment rates, which contribute to a favorable business environment for pharmaceutical companies and healthcare providers. These factors create opportunities for market expansion and investment in research and development for new treatments and therapies.In conclusion, the Psychotic Disorders market in Norway is witnessing growth due to changing customer preferences, emerging trends in the market, local special circumstances, and underlying macroeconomic factors. The demand for effective treatments, holistic approaches to care, and digital health solutions are driving the market forward. With a well-developed healthcare system and favorable economic conditions, Norway is poised to continue its growth in the Psychotic Disorders market.

Data coverage:

Data encompasses B2C enterprises. Figures are based on companies' revenues, international institutes data, and global consumer survey data. Revenues refer to the retail value and include sales taxes.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports and third-party data. Next, we use relevant key market indicators and data from country-specific associations such as healthcare spending per capita, medical product spending per capita, and gross domestic product per capita. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function. Data is modeled using current exchange rates.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Despite what some may think, mental health problems are common in the United States and around the world. Mental health issues, much like other health issues, can be mild, but can also be life altering, affecting the emotional, social, and psychological well-being of the person. Common types of mental illness include mood disorders, anxiety disorders, eating disorders, and personality disorders. Although symptoms of mental illness differ depending on the type of illness and seriousness of the problem, common symptoms of mental health issues include changes in sleeping and eating habits, social withdrawal, feelings of hopelessness, anger, and prolonged sadness, suicidal thoughts, and substance abuse. In 2022, it was estimated that around 36 percent of those in the U.S. aged 18 to 25 years and 29 percent of those aged 26 to 49 years suffered from some form of mental illness in the past year.